Disruption of IL-1β–IL-1R signaling by use of a monoclonal IL-1β antibody and an IL-1R antagonist, or by genetic disruption of IL-1R signaling lowered the growth of primary tumor and metastasis to lung and bone in the breast cancer mouse model20–22,26. Here, IL1R1 is linked to breast carcinoma.